Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DURECT Corporation (DRRX) SEC filings page on Stock Titan provides access to historical regulatory documents filed by this former Nasdaq-listed biopharmaceutical company. These filings trace DURECT’s evolution as a late-stage developer of epigenetic therapies, its financial reporting as a public issuer, and the steps that led to its acquisition by a subsidiary of Bausch Health Americas, Inc. and subsequent delisting.
For users analyzing DURECT’s business, earlier periodic reports and current reports on Form 8-K describe the company’s focus on larsucosterol, an investigational epigenetic modulator in clinical development for alcohol-associated hepatitis (AH), and disclose that the U.S. Food and Drug Administration granted larsucosterol Fast Track and Breakthrough Therapy designations for this indication. Other filings reference the company’s FDA-approved non-opioid analgesic POSIMIR, based on its SABER platform technology, and the sale of the ALZET osmotic pump product line.
Later filings are particularly important for understanding DRRX’s trading and registration status. A series of Forms 8-K in 2025 describe the Agreement and Plan of Merger with Bausch Health Americas, Inc., the commencement and terms of the tender offer for all outstanding DURECT shares, amendments to the merger agreement, and the completion of the merger on September 11, 2025. A Form 25 filed by The Nasdaq Stock Market LLC on that date documents the removal of DURECT’s common stock from listing on Nasdaq. Subsequently, a Form 15 filed on September 22, 2025 certifies the termination of registration of the common stock under Section 12(g) of the Exchange Act and the suspension of DURECT’s duty to file reports under Sections 13 and 15(d).
On Stock Titan, these filings are accompanied by AI-generated highlights that help explain key sections, such as change-of-control terms in merger-related 8-Ks, delisting notices, and the implications of Form 15 deregistration. Users can quickly identify documents related to corporate transactions, historical financial condition, and the regulatory history of larsucosterol and POSIMIR, while still having direct access to the full text as filed with the SEC.
Durect Corporation (DRRX) submits an S-8 post-effective filing that lists historical and current registrations of Common Stock under multiple employee plans and notes a 1-for-10 reverse stock split. The filing records specific registrations dating from October 5, 2000 through November 14, 2024, including shares registered under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan (as amended), the 2000 Stock Plan (as amended), the 2000 Directors' Stock Option Plan and legacy plans from Southern BioSystems and Southern Research Technologies. The company identifies itself as a Delaware entity with tax ID 94-3297098 and indicates it is a non-accelerated filer and a smaller reporting company. The filing explicitly states a 1-for-10 reverse stock split effected December 5, 2022 and shows specific share counts for each registration event.
Durect Corporation (DRRX) files a post-effective amendment to register shares reserved for employee plans. The filing lists numerous prior S-8 registrations and the share amounts reserved under various plans, including recent registrations of 18,000,000 shares under the 2000 Stock Plan (Aug 5, 2022), 40,000 shares under the Employee Stock Purchase Plan (Aug 10, 2023, after a 1-for-10 reverse split), and 2,000,000 shares under the 2000 Stock Plan (Nov 14, 2024, post-split). The document also notes a 1-for-10 reverse stock split effected Dec 5, 2022, and is signed by CFO Timothy M. Papp.
DURECT Corporation (DRRX) entered into an amended Agreement and Plan of Merger with Bausch Health Americas, Inc. under which each DURECT share will receive a cash amount plus one non-tradeable contingent value right (CVR). The CVRs together represent up to $350 million of potential additional net sales milestone payments, payable pro rata if milestones are met before the earlier of the 10‑year anniversary of first U.S. commercial sale and December 31, 2045, subject to the CVR Agreement. In‑the‑money stock options were accelerated and treated as shares for the offer; out‑of‑the‑money options unexercised at the Effective Time were canceled. Key documents including the Merger Agreement, Amendment No. 1, amended charter and bylaws, and a joint press release are incorporated by reference.
DURECT Corp (DRRX) filed a Form 25 notice with the SEC to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing includes the issuer's principal office address in Cupertino, California, and Nasdaq's certification that it has reasonable grounds to file the Form 25 and complied with applicable rules for withdrawal or delisting.
DURECT Corporation disclosed an amendment to its Schedule 14D-9 relating to a tender offer by BHC Lyon Merger Sub, Inc., a wholly owned subsidiary of Bausch Health Americas, Inc. The Offer provides $1.75 in cash per share plus one non-tradeable contingent value right (CVR) per share, which entitles holders to a pro rata share of up to $350,000,000 in milestone payments in the aggregate (reduced by any amounts paid to holders of Company Options under the Retention Plan). The Schedule 14D-9 amendment incorporates the Offer documents filed on August 12, 2025 and notes a joint press release dated September 11, 2025 between BHC and DURECT. The filing is signed by Timothy M. Papp, Chief Financial Officer.
James E. Brown, President & CEO and a director of DURECT Corporation (DRRX), reported acquisitions on 09/08/2025. The filing shows an acquisition of 10,000 common shares at a reported price of $1.30, bringing his direct common stock holdings to 283,412 shares. The filing also reports an acquisition of 10,000 stock options with a $1.30 exercise/conversion price, noting an exercisable/expiration schedule with a reference date of 10/14/2034 and total direct derivative holdings reported as 365,000. The option grant will vest in one‑sixteenth increments every three months, subject to continued service.
Durect Corp (DRRX) filed a Form 144 reporting a proposed sale of 5,500 common shares through Morgan Stanley Smith Barney LLC on 09/10/2025. The filing shows the shares were acquired and will be paid for on 09/10/2025 via a stock option exercise and payment in cash. The aggregate market value of the shares at filing is reported as $10,623.80 and the issuer’s number of shares outstanding is listed as 31,054,187. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information.
Timothy M. Papp, Chief Financial Officer of DURECT CORP (DRRX), reported stock-based transactions on 09/08/2025. He was granted an option for 110,000 shares with an exercise price of $1.30 that expires on 10/14/2034. The option vests in installments of one-sixteenth of the grant every three months, subject to continued service. The Form 4 also reports a transaction coded M reflecting acquisition of 110,000 common shares at $1.30, leaving total reported beneficial ownership of 431,659 shares following the transactions.
R. Scott Asen, a director of DURECT Corp (DRRX), reported an insider purchase on Form 4. The filing shows a purchase of 5,917 shares of DURECT common stock on 08/22/2025 at a price of $1.9194 per share. After the reported transaction the filing lists 2,672,529 shares beneficially owned by the reporting person in a direct capacity. The form also records 970,000 shares held indirectly (30,000 via The Asen Foundation and 940,000 via Asen & Co.) where the reporting person disclaims beneficial ownership except to the extent of pecuniary interest. The filing is signed by R. Scott Asen on 08/26/2025.
DURECT Corporation filed an amendment to its Schedule 14D-9 related to the cash-and-CVR tender offer by Bausch Health’s subsidiary to acquire all outstanding DURECT common shares. The offer price remains
The amendment updates the stated expiration of the offer, which is now scheduled to end at 5:00 p.m., New York City time, on
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
